Company profilePharmaceutical#58 of 1,318 in Pakistan2 DRAP alerts

Sante (Private) Limited

Pharmaceutical company · 225 brands · 175 molecules

Ranked #2 of 23 companies in Eye Conditions

225 registered products 77 pharmaceutical brands 175 distinct molecules 2 DRAP alerts

Company overview

225
registered products
77
pharmaceutical brands
175
distinct molecules
11
therapeutic classes
2
DRAP alerts

Sante (Private) Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 225 product registrations across 175 distinct molecules. It is the 58th largest registrant in Pakistan by product count, and ranks 2nd of 23 in Eye Conditions. Its portfolio is concentrated in Eye Conditions and Antiinflammatory Agents And Antiinfectives In Combination. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Sante

119 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

59
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202659

Top molecules by brand count

Eye37 brands
Dexamethasone13 brands
Tobramycin8 brands
Ofloxacin8 brands
Ear7 brands
Moxifloxacin6 brands
Timolol5 brands
Prednisolone5 brands

Therapeutic classes

Eye Conditions · 25Antiinflammatory Agents And Antiinfectives In Combination · 9Antiglaucoma Preparations And Miotics · 9Otologicals · 7Anti-Infective, Ophthalmologicals · 7Nasal Preparations · 6Other Ophthalmologicals, Lubricant · 5Anti-Infectives · 5Quinolone Antibacterials · 5Skin Conditions · 5Anti-Acne Preparations · 4

Conditions treated

Allergy/Infections · 12Dry Eye/Allergy · 8Glaucoma/Mydriasis · 4Hair Loss · 3Nasal Congestion · 3Fungal Infection · 3General Infections · 2Infection/Allergy · 2Infection/Pain · 2Acne/Topical · 1Hyperpigmentation · 1Pain Killers · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official100 products · Rs 66.67 – Rs 11,525.22
DVAGO38 products · Rs 92.15 – Rs 1,361
Servaid46 products · Rs 72.64 – Rs 876.61
Median across source: Rs 313.43

Regulatory record

2 alerts in the DRAP feed we track.

16. Recall Alert (Human) – CDL Karachi declared substandard products.
2026-03-11
Recall Alert: Drug Product; Santodex Opthalmic Ointment (Batch # BJ-082) by M/s Sante (Pri
2023-01-27

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 198 molecules not in this portfolio
Acetylsalicylic AcidAdapaleneAdapleneAlbuterolAminophyllineAmlodipine 6.95Mg Amlodipine Base
REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD. holds 36 molecules not in this portfolio
AcetazolamideAmoxicillinAmoxycillin BaseAtropineBenzyl BenzoateBrimonidine
SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 100 molecules not in this portfolio
AlbendazoleAmikacinAmlodipine BasylateAscorbic AcidAspirinBisoprolol

Get the full profile for Sante

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.